Results demonstrated that the modified adenovector induced anti-tumor responses and limited expression of TNF in normal tissue. These highly selective adenovectors may provide the basis for a potentially safe and effective treatment for cancers of the peritoneal space including ovarian and stomach cancers.
Richter King, GenVec’s senior VP of research, said: “Our new generation adenovector uses a combination of technologies which enable targeted delivery of our drug specifically to the tumor and control of gene expression within the tumor cells, avoiding toxicity in surrounding healthy tissue. This is an excellent example of how GenVec’s technology can be applied to provide new treatment strategies.”